Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- Study ID
- NCT06071520
- Status
- Completed
Conditions
- Primary Immune Thrombocytopenia
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Fostamatinib — DRUGPatient treated with fostamatinib in the period described
Study Details
Description of the use of fostamatinib in patients with PTI in the Andalusian region.
Key Dates
- Start date
- Mar 1, 2023
- Status verified
- Oct 2023
- Primary completion
- Apr 1, 2023
- Completion
- Jun 30, 2023
Study Design
- Enrollment
- 50 participants (actual)
Arms
- Arm: PTI patients treated with fostamatinibPatient with criteria of PTI who has been treated with fostamatinib in the time described
Primary Outcome Measure
Description of fostamatinib use [ Time Frame: From fostamatinib prescription first date ]
Related Studies
- Safety and Efficacy Study of PF-06835375 in Primary Immune ThrombocytopeniaPHASE2 · Recruiting · Pfizer · Greenville, North Carolina